X

Drug Profile

Research programme: tumour therapeutic vaccines - Wuhan Rhecogen Biotechnology

Alternative Names: Research programme: tumour therapeutic mRNA vaccines - Wuhan Rhecogen Biotechnology

Latest Information Update: 15 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wuhan Rhecogen Biotechnology
Class Antineoplastics; Cancer vaccines; RNA vaccines; Tumour cell vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Cancer

Most Recent Events

29 Sep 2021 Jiangsu Recbio Technology and Shenzhen Rhegen Biotechnology signs a joint venture agreement to establish Wuhan Rhecogen Biotechnology for developing tumour therapeutic vaccines
29 Sep 2021 Early research in Cancer in China (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com